Old drug, new hope? thalidomide tested for rare mast cell cancer

NCT ID NCT00769587

Completed Disease control Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested the drug thalidomide in people with systemic mastocytosis, a rare disease where too many mast cells build up in the body. The goal was to see if thalidomide could reduce the amount of disease in the bone marrow or other organs after 6 months. The trial included adults with aggressive or worsening disease who had already tried other treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: thalidomide
What this could lead to: If it works, this could point toward a treatment option for systemic mastocytosis that slows or reduces disease activity.
What could go wrong: This is a small, early-phase trial (Phase II) with no control group. Thalidomide has known side effects, and the results may not lead to a standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON NEOPLASTIC CONDITION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease Mastocytosis, Systemic precancerous condition systemic mastocytosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON NEOPLASTIC CONDITION PRECANCEROUS CONDITION

Contacts and locations

Show contact details

Locations

Centre Hospitalier Universitaire d'Amiens

Amiens, 80054, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.